User:Mr. Ibrahem/Ibritumomab

Ibritumomab, sold under the trade name Zevalin, is a medication used to treat non-Hodgkin's lymphoma. It is used following treatment with rituximab. It is given by gradual injection into a vein.

Common side effects include low red blood cells, low white blood cells, low platelets, weakness, fever, and nausea. Other side effects may include Stevens-Johnson syndrome and myelodysplastic syndrome. It is a monoclonal antibody attached to the radioactive element yttrium-90. The monoclonal antibody binds to CD20 found on B cells.

Ibritumomab was approved for medical use in the United States in 2002 and Europe in 2004. In the United States it costs 59,300 USD for a dose as of 2021. Use was not recommended by NHS Scotland in 2007 due to insufficient evidence of cost benefit.